We are live on
!
Find out more
BioMarin Pharmaceuticals
BMRN
BMRN
554 hedge funds and large institutions have $10.4B invested in BioMarin Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 211 increasing their positions, 164 reducing their positions, and 66 closing their positions.
New
Increased
Maintained
Reduced
Closed
44% more call options, than puts
Call options by funds: $96M | Put options by funds: $66.6M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
35% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 66
29% more repeat investments, than reductions
Existing positions increased: 211 | Existing positions reduced: 164
3% more funds holding
Funds holding: 538 → 554 (+16)
2.49% less ownership
Funds ownership: 97.97% → 95.48% (-2.5%)
7% less capital invested
Capital invested by funds: $11.2B → $10.4B (-$814M)
Holders
554
Holders Change
+16
Holders Change %
+2.97%
% of All Funds
6.82%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.14%
New
89
Increased
211
Reduced
164
Closed
66
Calls
$96M
Puts
$66.6M
Net Calls
+$29.5M
Net Calls Change
-$19.4M
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$184M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$101M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$79.5M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$59.8M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$57.7M |
Top Sellers
| 1 |
Squarepoint
New York
|
-$85.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$67.1M |
| 3 |
Morgan Stanley
New York
|
-$58M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$53.3M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$50.5M |
